However, MWA is already extensively applied in the clinical management of NSCLC, and phase I and II clinical trials for the use of Flt3L in conjunction with tumor adjuvant therapy have received approval.[42, 43] Therefore, we are in a position to seize the opportunity and are planning to seek authorization for clinical trials to ascertain the safety and effectiveness of the combined MWA and Flt3L treatment regimen for advanced NSCLC in the coming years. Here, FLT3LG is linked to neoplasm.